Shree Ganesh Remedies Ltd Guidance Report - SOIC x StockScans Report

as of Nov 2026

  1. GMP manufacturing block operational in H2 FY24 Partial - The FY23 annual report guided the GMP manufacturing block for advanced API intermediates to commence operations in H2 FY24, revised at Q1 FY24 to fully operational by Q3 FY24 with the GMP license awaited. By Q1 FY24 the FDA audit was concluded, the license was received and the plant was ready, but no disclosure confirms full GMP operations commenced.
  2. Minimum two new products launched every year Delivered - The FY20 annual report targeted launching minimum two new products every year via the newly commissioned pilot R&D plant and distillation setup. In Q2 FY27, commercial production commenced for two new pharmaceutical intermediates (anti-diabetic and cardiovascular), with 10+ projects in the pipeline across R&D, pilot and commercial scale-up.
  3. FY26 as year of consolidation and capacity building Delivered - At the Q4 FY25 call, management framed FY26 as a pivotal year of consolidation and capacity building, with anticipated near-term margin compression. FY26 closed with revenue ₹109.29 cr (+1% YoY), EBITDA ₹35.02 cr (-11%) and PAT ₹17.77 cr (-23%), which management said reflected the guidance as the business became structurally stronger.
  4. Sustainable EBITDA margins in the 24-28% range Partial - At the Q1 FY25 call, management committed to sustainable EBITDA margins within 24-28%, later reiterated as 24-26% over the long term at Q2 FY26. FY26 EBITDA margin was 32.0%, but Q1 FY27 fell to 23.3% and Q2 FY27 to 16.9%, with management expecting normalisation as sales return to earlier levels.
  5. Speciality and Fine Chemicals revenue contribution above 60% in coming years On track - At the Q4 FY25 call, management guided the Speciality and Fine Chemicals vertical to reach >60% of revenue in coming years, reiterated through the Q2 FY27 PPT. FY26 saw pharmaceutical intermediates at around 62% of revenue, and by Q2 FY27 pharma intermediates fell below 60% from >90% previously.
  6. Revenue doubling in 3 years Pending - At the Q2 FY27 call, management reaffirmed earlier guidance of doubling revenue in 3 years, saying "the direction is still clear, the size and the volume of the project is still intact". Q2 FY27 revenue was ₹23.29 cr, down 23% YoY, and H1 FY27 revenue ₹37.65 cr, down 32% YoY, against FY26 revenue of ₹109.29 cr.
  7. South-East Asia CRAMS revenue contribution from H2FY27 Partial - At the Q1 FY27 call, management guided South-East Asia CRAMS engagements to begin contributing to revenues from H2FY27, progressing in line with expectations. By Q2 FY27, commercial supplies were expected from Q1FY28, with pilot trials completed and batches undergoing stability testing and no revenue disclosed to date.
  8. CRAMS commercial production after pilot trials, subject to approvals On track - At the Q4 FY26 call, management guided CRAMS molecules (agrochemicals, pharma, electronics) to commence commercial production after the commercial trial phase, subject to customer and regulatory approvals. By Q2 FY27, Plant 7A construction and water trials were complete, and clarity on commercial supply was expected by Q4 FY27 with commercialization from Q1 FY28.
  9. Dahej common infrastructure investment in FY26 Delivered - At the Q4 FY25 call, management announced a decision to invest in common infrastructure and utilities at the Dahej site during FY26, funded through internal accruals. The FY26 annual report shows construction of common infrastructure, utilities and warehousing at Dahej progressing, with construction initiated per the Q1 FY27 and Q2 FY27 PPTs.
  10. European agrochemical product commercialised in Q2 CY2026 Missed - At the Q4 FY25 call, management guided an agrochemical product with approved source status for the European region to be commercialised in Q2 of calendar year 2026, later rescheduled at Q2 FY26 to commercial orders by Q4FY27. No commercialisation was disclosed for Q2 CY2026; two European molecules remain in positive progress as of Q2 FY27.
  11. Japanese client MoU commercial supplies from CY2025 Missed - At the Q4 FY25 call, management guided commercial supplies to a Japanese client (MoU signed for a speciality chemical) to commence later in CY2025, revised at Q2 FY26 to final approvals expected by mid-2026. The engagement was still advancing in trial stages through FY26 and Q2 FY27, with no commercial supply disclosed.
  12. Block 8 meaningful contribution by Q3FY25, 50-60% utilisation by FY26-end Partial - At the Q1 FY25 call, management guided Block 8, completed in FY24, to make a meaningful contribution by Q3FY25, with a 50-60% utilisation target by end of FY26 set at Q2 FY26. Block 8 commenced commercial production in Q1FY25 and Unit 1 utilisation ran 60-70% in FY26, but no specific Block 8 utilisation figure was disclosed for FY26-end.
  13. New pilot plant operational from Q2 FY26 Delivered - At the Q4 FY25 call, management guided commissioning of a new pilot plant implementing automation and flow chemistries in Q2FY26, revised at Q2 FY26 to operations in Q4FY26. The pilot facility was reported fully operational in Q4 FY26, though flow chemistry equipment was yet to be commercialised as of Q2 FY27.
  14. Block 7 commercial production from Q2FY27 Partial - At the Q2 FY26 call, management guided Block 7 at Ankleshwar Unit 1 to be completed by end of Q4FY26 with commercial production in Q1FY27, capex \~₹15 crores, rescheduled through several revisions to Q2FY27 with capex raised to \~₹20 crores. As of Q2 FY27, Block 7A construction was complete with water trials done but no commercial production disclosed, and CWIP rose to ₹16.30 cr on Block 7B investment.